Porton Pharma Solutions (SZSE:300363) Total Stockholders Equity : ¥5,679 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Porton Pharma Solutions Total Stockholders Equity?

Porton Pharma Solutions's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥5,679 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Porton Pharma Solutions's Book Value per Share for the quarter that ended in Mar. 2024 was ¥10.40. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Porton Pharma Solutions's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.34.

Porton Pharma Solutions Total Stockholders Equity Historical Data

The historical data trend for Porton Pharma Solutions's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Porton Pharma Solutions Total Stockholders Equity Chart

Porton Pharma Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

3,066.68

3,391.43

3,981.56

6,003.12

5,800.73

Porton Pharma Solutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															6,337.29	5,858.85	5,959.07	5,800.73	5,678.95

Porton Pharma Solutions (SZSE:300363) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Porton Pharma Solutions's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(5678.949	-	0)	/	546.038
	=	10.40

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Porton Pharma Solutions's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(274.115	+	1670.966)	/	5678.949
	=	0.34

Porton Pharma Solutions Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Porton Pharma Solutions's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Porton Pharma Solutions (SZSE:300363) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Porton Pharma Solutions Ltd (SZSE:300363) » Definitions » Total Stockholders Equity

Traded in Other Exchanges

N/A

Address

Fangzheng Avenue, Porton New Drug Outsourcing Service and R&D Center, Shuitu, Beibei District, Chongqing, CHN, 400714

Website

http://www.porton.cn

Porton Pharma Solutions Ltd is a China-based external manufacturing supplier of custom drug intermediates and Active Pharmaceutical Ingredients (APIs) to pharmaceutical companies. It is engaged in the process development activities and pilot-scale and commercial-scale manufacturing activities.

Executives

Wang Zhong Neng	Executives
Yu Yong Mei	Executives
Sun Min	Executives
Ji Yao Hui	Executives
Ju Nian Feng	Directors, executives
Tan Jun	Supervisors
Xu Ai Wu	Directors, executives
Guo Yong Qing	Independent director
	Director
	Director
Ceng Hui	Supervisors
Chen Bei	Executives

Porton Pharma Solutions (SZSE:300363) Headlines

No Headlines